CTI BioPharma has appointed Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors effective March 20, 2017.
Dr. Craig will replace Richard Love, interim President and CEO who will continue to serve on the company’s Board of Directors.
Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the US and Europe. He has worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016.
In connection with his appointment as President and Chief Executive Officer, Dr. Craig will be granted stock options to purchase 1.2 million shares of CTI BioPharma’s common stock at a per share price equal to the closing price of a share of the CTI BioPharma’s common stock on The NASDAQ Stock Market on his employment commencement date.